-
Media ReleaseReal-world data show Novartis drug Promacta® improves outcomes for ITP patients compared to other second-line therapies
-
Media ReleaseNovartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers
-
Media ReleaseNovartis data show psoriasis patients treated with Cosentyx® reported improvements in quality of life measures as early as Week 4
-
Media ReleaseNovartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease
-
Media ReleaseNovartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease
-
Media ReleaseAveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado
-
Media ReleaseNovartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease
-
Media ReleaseNovartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients
-
Media ReleaseNew AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1
-
Media ReleaseAveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients
-
Media ReleaseNovartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD
-
Media ReleaseNovartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders